Trials assess eligibility criteria for low-risk patients in active monitoring for invasive carcinoma, suggesting improvements in stratification methods.
More precise criteria and predictive biomarkers are needed to better stratify DCIS lesions and exclude women harboring invasive carcinomas from AM regimens.
No takes yet. Share an insight, caveat, or question.
Ataya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: